Your Tech Story

biotechnology

illumina

The success of Illumina, Inc. and how it helped fight COVID-19

With our generation constantly marching towards the IT sector and playing safe by working for a multinational company is a common view these days. This doesn’t mean that working for the IT sector harms us rather the advent of AI and ML is making a great contribution to every field. But, how many of us consider working for a biotechnology company and contributing to mankind from a different perspective? Our world has been attacked by an infectious pathogen that can stop time and turn everything upside down. People dying, the economy at the edge, unemployment, and we do not know what else we will witness. And, in this crisis, we are looking up to companies like Illumina to make a breakthrough and save the world from drowning.

What is Illumina?

Illumina is an American-based biotechnology company that develops systems to analyze genetic variation and biological function. The company dragged down the price of human genome sequencing from $1 million to $1,000 in 2014. Research organizations around the world, the pharmaceutical companies, and also academic institutions buy the products of Illumina. The company was founded in 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee. The company’s headquarters are currently based in San Diego, California.

About the founders

David Walt

David Walt went to the University of Michigan and acquired a bachelor’s degree in Chemistry. He later pursued his masters and Ph.D. in chemical biology. Currently, he is an Advisor at Illumina Ventures and a faculty member at the Harvard Medical School.

Larry Bock

Larry Bock was a famous American entrepreneur who died on 6th July 2016. He went to Bowdoin College and later to UCLA for his MBA. Apart from Illumina, Larry has also founded Nanosys, Caliper Life Sciences, and a few more companies.

John Stuelpnagel

John Stuelpnagel went to the University of California and has a bachelor’s degree in biochemistry. He was a venture capitalist at the CW group when he founded Illumina. Currently, he is the chairman of Fabric Genomics (also co-founder).

Anthony Czarnik

Anthony Czarnik is an American chemist who worked as an assistant professor at Ohio State University. Czarnik is the founder of RenoCares, a charity to support the drug addicts for rehab.

Mark Chee

Mark Chee went to the University of New South Wales followed by the University of Cambridge. He completed his Ph.D. in Molecular Biology. Currently, he is on the Board of Directors of Complete Genomics.

How Illumina was founded?

Back in 1998, the five founders established Illumina when Larry and John came to an understanding of what would be the BeadArray technology for Illumina. Shortly after founding the company, Illumina acquired Spyder Instruments which had the technology for high-throughput synthesis. In 2000, the company successfully filed its first IPO. The next year, the company started the new service, single nucleotide polymorphism genotyping.

Growth and Expansion

Eventually, the company started growing and designing solutions that can make our lives better. In 2007, Illumina acquired Solexa, a British company for approximately $600 million. Solexa was famous for commercializing genome sequencing technology who also bought the DNA colony sequencing technology in 2004. Illumina from the very beginning put immense effort to bring down the sky-high cost required for this kind of analysis and sequencing. In 2009, the company started its service for personal full genome sequencing for $48,000 which dropped to almost $19,000 by the next year.

Until 2010, Illumina sold systems and solutions only for research purposes but in 2010 it received approval for clinical tests as well. In 2011, the company acquired Epicentre Biotechnologies and next year launched HiSeq 2500, a very successful product of Illumina. This year the company also launched a cancer analysis service.

Famous people like Bill Gates and Jeff Bezos invested $100 million in Series A funding of the company. Since Illumina was working in the field of cancer testing as well, it partnered with Philips in 2017 to offer integrated genomic solutions for oncology. This year the company also opened its first commercial and customer training center.

How Illumina is fighting COVID-19?

Today, Illumina has provided solutions to more than 10,000 labs over 115 countries. And, due to the trust, they have built over time they are now connecting the local and global resources to fight against the pandemic. Next-generation sequencing or NGS is claimed to be very crucial for the study of patients during this pandemic. Illumina said that NGS can help gain information about patients and create a genetic tree that can show the path of transmission of this virus between two patients.

In response to this, the company designed Illumina COVIDSeq Test which is the first NGS test to receive emergency authorization use from the FDA. It can be only used in the US-based laboratories to perform tests at moderate and complex levels. The software toolkit of Illumina for COVID-19 has also been made free. The company is still working vehemently to help combat COVID-19 around the globe.

omnivis

OmniVis : Medical Science Meets Technology to Make the World Better and Disease Free

In the bigger picture, the present condition of our world is no less than mayhem. On the one hand, science is creating wonders with technology making our lives easier but on the other hand, millions of people are dying every day due to lack of treatment and development in medical science. Who is to blame for this? Are we way too ignorant to make significant contributions in the medical community? Or the price is so high that we have blatantly stopped trying? There are so many people dying every minute suffering from incurable diseases or due to late detection of infections in their body. Though the renowned and biggest research centres of our world are working together to invent instruments that can easily detect diseases, they are way too costly for common citizens.

With the zeal to alter the future of our world and stop it from destruction, four scholars of Purdue University, Katherine Clayton, Tamara Kinzer-Ursem, Jacqueline Linnes and Steve Wereley, came up with a unique solution to detect infectious and deadly diseases, which are both times efficient and affordable. With the mission to create affordable medical equipment, these four enlightened minds founded OmniVis, a company that will reach out to common people, help them detect disease and make out society better in terms of well-being.

Founders of OmniVis

Currently, Katherine Clayton is the CEO of the company with Ursem, Linnes and Wereley working as the Advisors.

Katherine Clayton Founder OmniVis
Image Source: halcyonhouse.org

Clayton, who is originally from San Francisco, went to Pursue University to complete her PhD in mechanical engineering. When she was an undergraduate student, she had already decided to work with healthcare products and make easy infection and disease detection equipment available to common people. When Clayton was a kid, she lost someone very close to her, due to the absence of better tools in the medical field, and hence, this was the beginning of her dream to do better for the community. She, with other three scholars, co-founded OmniVis in 2017, and since then, it has received worldwide support and funding.

Ursem is associated with Weldon School of Biomedical Engineering as an assistant professor which is under Purdue University. Her main area of research involves molecular biology, computational biology and neuroscience.

Linnes is also an assistant professor in the Weldon School of Biomedical Engineering as well. The Linnes Lab basically works to create technologies that can detect pathogens in a time-efficient way and stop them from propagating. She also has her own start-up, PotaVida founded in April 2010. The company’s goal is to develop pocket-friendly water purifiers and reach to the rural areas of the entire world.

Currently, Wereley is a professor at the School of Mechanical Engineering at Purdue University. His specialised fields are fluid mechanics and optics. He is also the founder of a company called Microfluidics Innovations.

The Idea

Since all of them belonged to a strong research background, OmniVis emerged out as a successful idea. More than a business, it is really an idea that inspired every company, research institutes throughout the world. OmniVis has created products that can detect Cholera with less than an hour with its concepts and techniques.

Currently, OmniVis works with iPhone but soon it will incorporate the software in Android and start testing the beta version. OmniVis works in a simple process with few steps, collect the sample, detect pathogen and map location. OmniVis detects and shows the location on the map from where the sample was taken to alert the authorities. And all of these are getting done within 30 minutes with the technology of OmniVis.

The Achievements

In 2017, OmniVis acquired the first place in Vodafone Wireless Innovation Project funded by Vodafone Foundation. In 2018, OmniVis was nominated for World Changing Idea Finalist. In June 2018, the company received Phase I SBIR Grant from National Science Foundation. In the same year, OmniVis won the 2018 AMPLIFY Pitch Competition where participants from 46 different countries participated. After winning the Biological Innovation Award in February 2019, OmniVis took a step ahead and expanded out of Indiana. In May 2019, the team reached out to Bangladesh and shared the benefits of OmniVis products with them.

Some of the major investors at OmniVis are Vodafone Foundation, Deloitte, Fast Company, Purdue University, halcyon and many more.